Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: JPM who wrote (804)	3/30/1998 8:53:00 AM
From: ADEL 7	Read Replies (1) \| Respond to of 9523

Only 10% of men who are supposed to take the drug will take it and the other 90% will remain impotent. Mr. knowledge check your facts first before you start using your calculator. Good day.....

To: JPM who wrote (804)	3/30/1998 4:02:00 PM
From: Barron Von Hymen	Respond to of 9523

You're right, it looks like I made a terrible math error.

To: JPM who wrote (804)	3/30/1998 6:27:00 PM
From: Barron Von Hymen	Read Replies (1) \| Respond to of 9523

Although my math was off, I do believe the Motley Fools have been reading my posts. Mar 30, 1998 (6:10 PM ET) - The Motley Fool Evening News Pharmaceutical firm Pfizer Inc. (NYSE:PFE - news) continued to rise in heavy trading, gaining $1 15/16 to $97 11/16 following the Food and Drug Administration's approval on Friday of male impotence drug Viagra. The company has declined to speculate on potential sales, but has said the drug will cost $7 a tablet wholesale. An estimated 30 million men in the U.S. are affected by erectile dysfunction. Assuming a mere one-tenth of these men opt to use Viagra just once a week, that could mean up to $1.1 billion a year for Pfizer -- no small amount for a company that last year reported sales of $12.5 billion. If a third of those 30 million men decided to use Viagra once a week, Pfizer could rake in $3.64 billion per annum in the U.S. alone. Viagra is expected to be available by prescription by mid-April. Pfizer has two other drugs to boost sales this year, as well. It started selling Trovan, a new antibiotic, earlier this year, and it expects to begin selling Zeldox, a new drug for schizophrenia, later this year.